306 related articles for article (PubMed ID: 34850406)
1. Upgrade of an old drug: Auranofin in innovative cancer therapies to overcome drug resistance and to increase drug effectiveness.
Gamberi T; Chiappetta G; Fiaschi T; Modesti A; Sorbi F; Magherini F
Med Res Rev; 2022 May; 42(3):1111-1146. PubMed ID: 34850406
[TBL] [Abstract][Full Text] [Related]
2. [Potential Anticancer Activity of Auranofin].
Momose I; Onodera T; Kawada M
Yakugaku Zasshi; 2021; 141(3):315-321. PubMed ID: 33642497
[TBL] [Abstract][Full Text] [Related]
3. Potential Anticancer Activity of Auranofin.
Onodera T; Momose I; Kawada M
Chem Pharm Bull (Tokyo); 2019; 67(3):186-191. PubMed ID: 30827998
[TBL] [Abstract][Full Text] [Related]
4. Repurposing of auranofin: Thioredoxin reductase remains a primary target of the drug.
Zhang X; Selvaraju K; Saei AA; D'Arcy P; Zubarev RA; Arnér ES; Linder S
Biochimie; 2019 Jul; 162():46-54. PubMed ID: 30946948
[TBL] [Abstract][Full Text] [Related]
5. Repurposing of the gold drug auranofin and a review of its derivatives as antibacterial therapeutics.
Liu Y; Lu Y; Xu Z; Ma X; Chen X; Liu W
Drug Discov Today; 2022 Jul; 27(7):1961-1973. PubMed ID: 35192926
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells.
Marzano C; Gandin V; Folda A; Scutari G; Bindoli A; Rigobello MP
Free Radic Biol Med; 2007 Mar; 42(6):872-81. PubMed ID: 17320769
[TBL] [Abstract][Full Text] [Related]
7. Cross-talk between two antioxidants, thioredoxin reductase and heme oxygenase-1, and therapeutic implications for multiple myeloma.
Raninga PV; Di Trapani G; Vuckovic S; Tonissen KF
Redox Biol; 2016 Aug; 8():175-85. PubMed ID: 26795735
[TBL] [Abstract][Full Text] [Related]
8. In vitro antineoplastic effects of auranofin in canine lymphoma cells.
Zhang H; Rose BJ; Pyuen AA; Thamm DH
BMC Cancer; 2018 May; 18(1):522. PubMed ID: 29724201
[TBL] [Abstract][Full Text] [Related]
9. Auranofin inactivates Trichomonas vaginalis thioredoxin reductase and is effective against trichomonads in vitro and in vivo.
Hopper M; Yun JF; Zhou B; Le C; Kehoe K; Le R; Hill R; Jongeward G; Debnath A; Zhang L; Miyamoto Y; Eckmann L; Land KM; Wrischnik LA
Int J Antimicrob Agents; 2016 Dec; 48(6):690-694. PubMed ID: 27839893
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationships in a series of auranofin analogues showing remarkable antiproliferative properties.
Landini I; Massai L; Cirri D; Gamberi T; Paoli P; Messori L; Mini E; Nobili S
J Inorg Biochem; 2020 Jul; 208():111079. PubMed ID: 32497830
[TBL] [Abstract][Full Text] [Related]
11. Unveiling the Potential of Innovative Gold(I) and Silver(I) Selenourea Complexes as Anticancer Agents Targeting TrxR and Cellular Redox Homeostasis.
De Franco M; Saab M; Porchia M; Marzano C; Nolan SP; Nahra F; Van Hecke K; Gandin V
Chemistry; 2022 Dec; 28(70):e202201898. PubMed ID: 36106679
[TBL] [Abstract][Full Text] [Related]
12. Dual targeting of the thioredoxin and glutathione antioxidant systems in malignant B cells: a novel synergistic therapeutic approach.
Kiebala M; Skalska J; Casulo C; Brookes PS; Peterson DR; Hilchey SP; Dai Y; Grant S; Maggirwar SB; Bernstein SH
Exp Hematol; 2015 Feb; 43(2):89-99. PubMed ID: 25448488
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti-PD-L1 antibody for treatment of triple-negative breast cancer.
Raninga PV; Lee AC; Sinha D; Shih YY; Mittal D; Makhale A; Bain AL; Nanayakarra D; Tonissen KF; Kalimutho M; Khanna KK
Int J Cancer; 2020 Jan; 146(1):123-136. PubMed ID: 31090219
[TBL] [Abstract][Full Text] [Related]
14. Auranofin repurposing for lung and pancreatic cancer: low CA12 expression as a marker of sensitivity in patient-derived organoids, with potentiated efficacy by AKT inhibition.
Deben C; Boullosa LF; Fortes FR; De La Hoz EC; Le Compte M; Seghers S; Peeters M; Vanlanduit S; Lin A; Dijkstra KK; Van Schil P; Hendriks JMH; Prenen H; Roeyen G; Lardon F; Smits E
J Exp Clin Cancer Res; 2024 Mar; 43(1):88. PubMed ID: 38515178
[TBL] [Abstract][Full Text] [Related]
15. Metal- and Semimetal-Containing Inhibitors of Thioredoxin Reductase as Anticancer Agents.
Gandin V; Fernandes AP
Molecules; 2015 Jul; 20(7):12732-56. PubMed ID: 26184149
[TBL] [Abstract][Full Text] [Related]
16. Repurposing Auranofin and Evaluation of a New Gold(I) Compound for the Search of Treatment of Human and Cattle Parasitic Diseases: From Protozoa to Helminth Infections.
Feng L; Pomel S; Latre de Late P; Taravaud A; Loiseau PM; Maes L; Cho-Ngwa F; Bulman CA; Fischer C; Sakanari JA; Ziniel PD; Williams DL; Davioud-Charvet E
Molecules; 2020 Nov; 25(21):. PubMed ID: 33139647
[TBL] [Abstract][Full Text] [Related]
17. Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl-dependent and -independent mechanisms.
Chen X; Shi X; Zhao C; Li X; Lan X; Liu S; Huang H; Liu N; Liao S; Zang D; Song W; Liu Q; Carter BZ; Dou QP; Wang X; Liu J
Oncotarget; 2014 Oct; 5(19):9118-32. PubMed ID: 25193854
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of auranofin-induced apoptosis in MCF-7 human breast cells by selenocystine, a synergistic inhibitor of thioredoxin reductase.
Liu C; Liu Z; Li M; Li X; Wong YS; Ngai SM; Zheng W; Zhang Y; Chen T
PLoS One; 2013; 8(1):e53945. PubMed ID: 23342042
[TBL] [Abstract][Full Text] [Related]
19. Auranofin Resistance in
Ma CI; Tirtorahardjo JA; Jan S; Schweizer SS; Rosario SAC; Du Y; Zhang JJ; Morrissette NS; Andrade RM
Front Cell Infect Microbiol; 2021; 11():618994. PubMed ID: 33816332
[TBL] [Abstract][Full Text] [Related]
20. Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells.
Li H; Hu J; Wu S; Wang L; Cao X; Zhang X; Dai B; Cao M; Shao R; Zhang R; Majidi M; Ji L; Heymach JV; Wang M; Pan S; Minna J; Mehran RJ; Swisher SG; Roth JA; Fang B
Oncotarget; 2016 Jan; 7(3):3548-58. PubMed ID: 26657290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
